V8 Peptides — Engineered Performance
Research Library
Semax Cognitive Function Research: Rodent Behavior Models
SemaxPreclinical

Semax Cognitive Function Research: Rodent Behavior Models

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer: Published Semax studies use rats and mice to test learning (passive and conditioned avoidance), anhedonia-like behavior (sucrose preference) and anxiety after early-life or acute stress. Intranasal and intraperitoneal routes appear in these papers, and the reported readouts are behavioral scores alongside hippocampal BDNF and trkB measures. They are animal findings, not claims about people. Laboratory research use only.

Cognitive-signaling research, defined narrowly

"Cognitive function" is a phrase that invites overreach. In a laboratory paper it means something specific: a rodent was placed in a defined task, a behavior was scored, and the score was compared with a control group. This guide goes through the behavioral tasks that appear in published Semax work and states what each paper reported. It does not make claims about attention, memory or mood in people, and it does not recommend any use.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues match positions 4–7 of adrenocorticotropic hormone (ACTH), and the Pro-Gly-Pro tail was added to slow enzymatic degradation. V8 Peptides supplies it as a 15 mg lyophilized research vial; details are on the Semax product page. The compound's broader background is in the Semax research overview and the what is Semax explainer. This article is narrower: it is about the behavioral models.

The tests, in plain terms

Passive avoidance. An animal learns to avoid a compartment where it previously received a mild aversive stimulus. Latency to enter on a later trial is the readout. It is a learning-and-memory task, and results depend on the stimulus, the interval and the animal's baseline activity.

Conditioned avoidance. The animal learns to respond to a cue by moving to avoid an aversive event. The count of avoidance reactions across sessions is the readout.

Sucrose preference. A rat is offered water and a sucrose solution. A fall in preference after chronic stress is read as anhedonia-like behavior, and a reversal as a protective effect of an intervention.

Forced swim. Immobility time is scored. It is widely used in the wider literature and often debated; it is described here only so readers recognize the name, since the Semax papers cited below lean on other readouts.

Open-field and anxiety tests. Activity, rearing and time in the center are scored to estimate emotional reactivity and anxiety-like behavior.

What the published papers reported

A hippocampal study reported that a single intranasal application of Semax at 50 µg/kg in rats produced a maximal 1.4-fold increase in BDNF protein, a 1.6-fold increase in trkB tyrosine phosphorylation, a 3-fold increase in exon III BDNF mRNA and a 2-fold increase in trkB mRNA. The Semax-exposed animals showed a distinct increase in the number of conditioned avoidance reactions, and the authors suggested that Semax affects cognitive brain function by modulating the hippocampal BDNF/trkB system [1].

A study of route in white rats used passive avoidance acquisition for the nootropic readout and the Randall-Selitto paw-withdrawal test for pain sensitivity. It reported that Semax showed nootropic and analgesic activity after intraperitoneal administration, that intranasal administration was more potent for learning improvement than intraperitoneal administration, and that intranasal administration did not affect pain sensitivity, which the authors read as different mechanisms and brain structures for the two effects [2].

In a chronic unpredictable stress model in male Sprague-Dawley rats, daily intraperitoneal administration of a low amount (60 nmol/kg) of Semax or the melanocortin agonist Melanotan II reversed or substantially attenuated stress-induced anhedonia, suppression of body-mass gain, adrenal hypertrophy and a decrease in hippocampal BDNF. The same paper pairs the behavioral scores with hippocampal measurements, which is the usual pattern in this literature [3].

In early-life stress, Semax at 0.05 mg/kg given intranasally daily from postnatal day 15 to 28 was reported to weaken the effect of neonatal maternal deprivation on body mass and to normalize anxiety in one-month-old rats [4]. A study of acute restraint stress gave Semax at 100 µg/kg 30 minutes before the stressor and reported attenuated stress-induced behavioral alterations, together with a large number of differentially expressed hippocampal genes at 4.5 hours [5].

Summary table of the cited models

ModelSpeciesRoute as reportedBehavioral readoutMolecular readout
Single application, hippocampusRatIntranasalConditioned avoidance reactionsBDNF, trkB protein and mRNA [1]
Learning and pain, route comparisonWhite ratIntranasal vs intraperitonealPassive avoidance; paw-withdrawalNone in abstract [2]
Chronic unpredictable stressMale Sprague-Dawley ratIntraperitoneal, dailySucrose preference, body massHippocampal BDNF [3]
Neonatal maternal deprivationWhite ratIntranasal, dailyAnxiety-type behavior, body massNone in abstract [4]
Acute restraint stressMale ratRoute per paperBehavioral alterationsHippocampal RNA-seq [5]

Reading the studies together

Two things stand out. First, the behavioral work is paired with molecular readouts in the same animals, most often BDNF and trkB, so the papers argue for a mechanism and not only for a score. Second, the published amounts and routes vary widely (µg/kg, nmol/kg, mg/kg, intranasal and intraperitoneal), so results from one paper cannot be transplanted into another without rethinking everything about the model.

A third point is easy to miss: several papers compare Semax with another peptide or with its own fragments, so the control group is not always vehicle alone. When citing a number, cite the comparison it came from.

Planning a behavioral study: what the literature implies

A design that follows the published approach would define, before the first animal is handled:

1. The task and its scoring rule, including who scores and whether they are blinded. 2. The route, because the intranasal and intraperitoneal results in one paper differed in the same task [2]. 3. The timing of administration relative to training and testing. 4. A vehicle control and, where relevant, a comparator. 5. A molecular endpoint (hippocampal BDNF protein or mRNA is the one most often paired with behavior). 6. The sample size and how animals are allocated across cages and test days.

Stock arithmetic is the last step and the most error-prone. Papers state amounts per kilogram of body mass. The amount per animal is that figure multiplied by the animal's body mass in kilograms, and the volume to prepare is the amount divided by the stock concentration. Stock concentration itself is the vial mass divided by the diluent volume, and the reconstitution calculator performs it. Record each figure before the first administration.

QuantityFormula
Stock concentration (mg/mL)Vial mass (mg) ÷ diluent volume (mL)
Amount per animal (µg)Reported amount (µg/kg) × body mass (kg)
Volume per animal (µL)Amount per animal (µg) ÷ stock (µg/µL)

Material and handling considerations

Behavioral readouts are noisy, so material variability should not add to the noise. Confirm the lot's documentation before starting; the COA page shows how it is laid out where published, and the Semax purity testing article explains what an identity and purity test has to confirm. Reconstitute with sterile diluent, avoid vigorous shaking, store as the product page states (2–8 °C, −20 °C for long-term, protected from heat, moisture and light) and keep a record of every freeze–thaw. The selank vs semax comparison is useful context for readers deciding between the two peptides in behavioral models.

Confounds that matter in behavioral work

Behavioral studies with peptides share a short list of confounds that deserve explicit mention in any write-up. Handling stress is first: intranasal administration requires restraint, and repeated handling is itself a stressor, so vehicle controls must be handled identically. Time of day is second, because rodents are nocturnal and performance differs across the light cycle. Sex and estrous stage matter, and several of the cited papers used males only, which limits what can be said about females. Locomotor activity can masquerade as cognition: an animal that moves more may enter a compartment sooner, so activity should be measured alongside learning scores. Finally, experimenter blinding is easy to omit and hard to defend omitting.

One further point is worth making about route comparisons. Intranasal and intraperitoneal administration deliver the same compound to different compartments at different rates, so a difference in outcome between routes does not isolate the mechanism; it only shows that route matters in that task. The authors of the route study read the pain and learning results as pointing to separate mechanisms [2], and that is an interpretation, not a measurement.

What these studies do not show

They do not show that Semax changes cognition in any species beyond the one tested. They do not show that the BDNF changes cause the behavior; the papers are correlational on that point. They do not establish a window of effect, since time courses vary, and several of them are by overlapping research groups, which limits independence. They do not support any claim outside the laboratory.

Frequently asked questions

What does "cognitive function research" mean for Semax?

In published papers it means scored behavior in rodent tasks such as passive avoidance, conditioned avoidance, sucrose preference and anxiety tests, paired with molecular readouts.

Which route do the studies use?

Both intranasal and intraperitoneal routes appear. One study compared them in the same task and reported that the intranasal route was more potent for learning improvement.

What was reported about BDNF?

After a single intranasal application at 50 µg/kg in rats, hippocampal BDNF protein rose up to 1.4-fold, trkB phosphorylation 1.6-fold, and exon III BDNF and trkB mRNA 3-fold and 2-fold.

Did Semax affect pain sensitivity?

In the route-comparison study, intraperitoneal administration affected pain sensitivity and intranasal administration did not.

What stress models were used?

Chronic unpredictable stress, acute restraint stress and neonatal maternal deprivation, with sucrose preference, body mass and anxiety-type behavior as readouts.

Why use more than one behavioral test?

Each test captures a different slice of behavior, so a conclusion that rests on one score is fragile. Pairing behavioral and molecular readouts is the common pattern.

How do I turn µg/kg into a volume?

Multiply by body mass in kilograms for the amount per animal, then divide by the stock concentration. The site calculator handles the stock concentration step.

How is Semax supplied by V8 Peptides?

As a 15 mg lyophilized powder in a sealed glass vial, stated purity of at least 98% by HPLC, formula C37H51N9O10S.

How should it be stored?

At 2–8 °C, or −20 °C for long-term storage, protected from heat, moisture and light.

Do these results apply to people?

No claim is made. They are animal findings reported in the cited papers, and this site sells the material for laboratory research only.

Research-use statement

This product is supplied for laboratory research use only. It is not a drug, food or cosmetic, and it is not for human or animal consumption. This article summarizes published animal studies and makes no recommendation. See the research library and the shop for related materials.

Related reading: Semax Gene Expression in Rat Brain: Studies Compared, Semax Intranasal Route in Preclinical Research Studies, Semax in Ischemia Models: What Mechanism Studies Show.

References

  1. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108
  2. Manchenko DM, et al. Nootropic and analgesic effects of Semax following different routes of administration. Ross Fiziol Zh Im I M Sechenova. 2010. PMID: 21268834
  3. Inozemtseva LS, Yatsenko KA, Glazova NY, Kamensky AA, Myasoedov NF, Levitskaya NG, et al. Antidepressant-like and antistress effects of the ACTH(4–10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology. 2024;984:177068. doi:10.1016/j.ejphar.2024.177068
  4. Volodina MA, Sebentsova EA, Glazova NY, Levitskaya NG, Andreeva LA, Manchenko DM, et al. Semax Attenuates the Infl uence of Neonatal Maternal Deprivation on the Behavior of Adolescent White Rats. Bull Exp Biol Med. 2012;152(5):560-563. doi:10.1007/s10517-012-1574-2
  5. Filippenkov IB, Stavchansky VV, Glazova NY, Sebentsova EA, Remizova JA, Valieva LV, et al. Antistress Action of Melanocortin Derivatives Associated with Correction of Gene Expression Patterns in the Hippocampus of Male Rats Following Acute Stress. IJMS. 2021;22(18):10054. doi:10.3390/ijms221810054

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.